Fulgent Genetics Inc(FLGT) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. The company is headquartered in Temple City, California and currently employs 123 full-time employees. The firm offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The firm has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The firm's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.

Current Price

$74.64

RSI

34.677

Beta:

1.621364

March 08, 2021
15.9M
110.5M

3415.500 %
218.140 %
67428.743 %
336.374 %

$421,712,000
$32,528,000
$21,351,000
$18,730,000
$18,276,000
1196.458 %
52.349 %
13.994 %
2.484 %

$286,842,000
$-368,000
$-5,571,000
$-3,525,000
$-4,427,000
100.128 %
1413.859 %
-36.726 %
25.589 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.